Dana Sullivan
Reads the trial before the press release, and says plainly when a question was never asked.
Dana Sullivan covers the clinical evidence behind GLP-1 medicines for This GLP: which trial produced a number, in whom, and at what dose. How long a study ran, and how many people were still in it at the end, belong beside the result rather than in a footnote. The work is mostly reading — protocols, prescribing labels, and the supplementary tables that carry the dropout rates — and then writing down what a study can and cannot support. Where a question has not been studied, the page says so rather than filling the gap with a plausible sentence. No degrees, affiliations, or clinical credentials are claimed here; the sourcing is the credential, and every figure links to the record it came from.
What they cover
- Randomized trial design and endpoints
- FDA prescribing information and label changes
- Reported adverse events and dropout rates
- Dose-response and titration schedules
- Compounded versus FDA-approved formulations
- Reading a study's limitations section